Auris Medical: Rises on positive data from tumor-inhibition animal study

Altamira Therapeutics

21/06/2021 17:00

** U.S.-listed shares of Switzerland-based biotech co 
 EARS.O  rise 8.1% to $3.59
    ** Co reports positive results from animal study employing
its OligoPhore tech 
    ** Data showed significant inhibition of tumor growth in
adult T-cell leukemia lymphoma (ATLL) - EARS
    ** ATLL is a cancer of the immune system's T-cells; it can
be found in blood, lymph nodes, skin or other parts of body
    ** Significant reduction in tumor size, spleen size and
peripheral blood lymphocyte counts was seen in mice - EARS
    ** EARS's OligoPhore tech delivers nucleic acid payloads
into target cancer cells 
    ** Study data published in peer-reviewed journal
Nanomaterials
    ** YTD, stock up ~37%

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))